STATE HIGHER EDUCATIONAL ESTABLISHMENT "UZHHOROD NATIONAL UNIVERSITY", UZHHOROD, UKRAINE.
Pol Merkur Lekarski. 2023;51(4):330-333. doi: 10.36740/Merkur202304105.
Aim: To investigate the possible relationship between fecal calprotectin (FC) level and ultrasound indicators of steatosis and fibrosis wich defined by attenuation coefficient (AC) and liver stiffness (LS) from two-dimensional (2D) shear-wave elastography (SWE) in patients with metabolically associated fatty liver disease (MAFLD).
Materials and Methods: The study included 110 persons with MAFLD; mean age 51.3±4.8 years, 65 (59.1%) men. There were used laboratory, sonography and statistical methods.
Results: Stage S1 of steatosis was diagnosed in 42 (38.2%), S2 - in 56 (50.9%), S3 - only in 12 (10.9%) MAFLD patients. The carbohydrate metabolism disorders were found in 62 (56.4%); 38 (34.5%) patients among them suffered from type 2 diabetes. The lipid metabolism disorders were diagnosed in the vast majority of patients included in this study. The minimal excess of fecal calprotectin (FC) was detected in 72 MAFLD patients (65.5%), the moderate increase of FC was found in 12 persons, the FC more than 10-fold excess of the norm was observed in only 8 MAFLD patients. FC levels were significantly elevated in MAFLD patients with a S2-S3 compared to those with a S1 (75.8 [42.9-112.1] vs. 46.3 [28.2-65.4], p<0.01).
Conclusions: Fecal calprotectin levels are significantly elevated in patients with MAFLD. Future studies are warranted to establish the definitive role and clinical utility of FC as a potential biomarker of probably liver steatosis as well as other diseases associated with methabolic syndrome and its complications.
旨在探讨代谢相关脂肪性肝病（MAFLD）患者粪便钙卫蛋白（FC）水平与衰减系数（AC）和二维（2D）剪切波弹性成像（SWE）肝硬度（LS）定义的脂肪变性和纤维化的超声指标之间的可能关系。
本研究纳入了 110 例 MAFLD 患者；平均年龄 51.3±4.8 岁，65 例（59.1%）为男性。使用了实验室、超声和统计方法。
S1 期脂肪变性诊断 42 例（38.2%），S2 期 56 例（50.9%），S3 期仅 12 例（10.9%）。发现糖代谢紊乱 62 例（56.4%）；其中 38 例（34.5%）患有 2 型糖尿病。绝大多数纳入本研究的患者均诊断出脂代谢紊乱。72 例 MAFLD 患者（65.5%）粪便钙卫蛋白（FC）轻度升高，12 例中度升高，仅 8 例 MAFLD 患者 FC 超过正常值 10 倍。S2-S3 期 MAFLD 患者 FC 水平明显高于 S1 期患者（75.8[42.9-112.1]比 46.3[28.2-65.4]，p<0.01）。
MAFLD 患者 FC 水平显著升高。未来需要进一步研究以确定 FC 作为可能的肝脂肪变性以及与代谢综合征及其并发症相关的其他疾病的潜在生物标志物的明确作用和临床应用价值。
